Interstate 65 Construction: Downtown Indianapolis

Portions of Interstate 65 in downtown Indianapolis will be closed for bridge repairs beginning on or after June 1. Construction may impact travel to IU Health facilities in the area. Learn more.

Institutional Biosafety Committee

OverviewSlice

Institutional Biosafety Committees (IBCs) are essential for institutional oversight of research that involves the use of biohazardous agents, including recombinant and/or synthetic nucleic acid molecules. The IBC functions to ensure that research activities conducted within the Indiana Center for Biomedical Innovation are in compliance with federally-mandated responsibilities and obligations, as described in the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, the Centers for Disease Control and Prevention (CDC) select agent guidelines, and U.S. Department of Agriculture (USDA) select agent regulations. The IBC consists of staff and community representatives who have responsibility for reviewing all research activities.

Research Activities Reviewed: 

Infectious agents (bacteria, viruses, protozoans, fungi, etc.) Biologically derived toxins Human and/or non-human primate blood, body fluids, cells or tissue culture Recombinant DNA Synthetic nucleic acid molecules Transgenic animals, invertebrates, and/or plants Artificial gene transfer Prions Dual-use technologies Synthetic Biology

The IBC oversees biosafety policies and procedures and reviews individual research protocols for biosafety concerns. Additionally, the IBC coordinates with the IACUC when animals are used and the IRB when human subjects are involved. For research projects involving any of the activities outlined above, complete the IBC Protocol Registration Form and submit it to the committee for approval. The link for submission is on the form.

Overview

Institutional Biosafety Committees (IBCs) are essential for institutional oversight of research that involves the use of biohazardous agents, including recombinant and/or synthetic nucleic acid molecules. The IBC functions to ensure that research activities conducted within the Indiana Center for Biomedical Innovation are in compliance with federally-mandated responsibilities and obligations, as described in the NIH Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, the Centers for Disease Control and Prevention (CDC) select agent guidelines, and U.S. Department of Agriculture (USDA) select agent regulations. The IBC consists of staff and community representatives who have responsibility for reviewing all research activities.

Research Activities Reviewed: 

Infectious agents (bacteria, viruses, protozoans, fungi, etc.) Biologically derived toxins Human and/or non-human primate blood, body fluids, cells or tissue culture Recombinant DNA Synthetic nucleic acid molecules Transgenic animals, invertebrates, and/or plants Artificial gene transfer Prions Dual-use technologies Synthetic Biology

The IBC oversees biosafety policies and procedures and reviews individual research protocols for biosafety concerns. Additionally, the IBC coordinates with the IACUC when animals are used and the IRB when human subjects are involved. For research projects involving any of the activities outlined above, complete the IBC Protocol Registration Form and submit it to the committee for approval. The link for submission is on the form.